Gliknik discovers and develops biologic drugs for people with cancer and immune disorders. Gliknik management and its Board of Directors have deep industry expertise with a track record for discovering, developing, and bringing to market drugs and generating successful exits for investors.

Home

You are here: Home

  • We have taken a bit of a different path than that taken by other companies – and it seems to be working. We are finding and advancing multiple drugs that may help a lot of people with cancers and autoimmune disorders.

    – David Block, Gliknik Co-Founder & CEO

  • I’m passionate about finding better treatment options for cancer patients. Before I co-invented the cancer immunomodulators now licensed to Gliknik, I was one of the inventors of using anti-PD-L1 antibodies for the treatment of cancer. By harnessing the power of the immune system, GL-0817, targeted against cancer protein MAGE-A3, is designed as a new approach to cancer. It has a number of built-in features that may make a difference for people living with various cancers, including of the head and neck.

    – Scott Strome, M.D., Professor & Chairman Otolaryngology – Head & Neck Surgery, University of Maryland School of Medicine

  • Although I’ve been a part of a number of successful drug launches at Incyte Corporation, DuPont and Merck, I’ve seen an even larger number of program failures. The Gliknik team is taking on immense challenges as it seeks to discover and develop drugs for cancers and immune disorders, and I believe they’ve got what it takes to succeed.

    – Paul Friedman, M.D., Gliknik Board Member

  • For me, it’s a matter of pride that important drugs from my labs have made it to the market and are being used so widely in combination therapy for HIV and more recently in Hepatitis C. I’m also proud to be on the Board of Gliknik, which I expect will generate significant new treatment options for people living with autoimmune diseases and cancers. I enjoy sharing what I have learned starting and selling several biotech companies.  

    – Raymond Schinazi, Ph.D., D.Sc., Gliknik Board Member

1234

Pfizer Now Advancing GL-2045

GL-2045, our first stradomerTM advancing in development, has shown promising results in a broad range of preclinical tests and is now being developed by Pfizer as a potential treatment for a variety of autoimmune diseases.

Gliknik and Pfizer entered into a licensing agreement for GL-2045 development in September 2013. Today, the compound is in large-scale manufacturing and we expect it to rapidly progress into clinical development.

Learn more…

Featured Pipeline Program

By harnessing the power of the immune system, GL-0817 is designed as a new approach to cancer. It has a number of built-in features not available in any competitive cancer therapeutic vaccine. To date, GL-0817 has been studied in people living with head and neck cancers and with multiple myeloma.

From the earliest stages of research, Gliknik researchers attempt to ensure that our areas of scientific focus are on unmet medical needs where we can create a competitive advantage and develop medicines that will make a difference in the lives of patients.

Learn more…

Our Approach

At Gliknik, our mission is to discover and develop truly innovative biologics for people living with cancer and immune disorders. Headquartered in downtown Baltimore’s medical research community, Gliknik’s expertise is in modulation of the immune system to fight disease.

Our perseverance and determination to make a difference in the lives of individuals with cancer and autoimmune disease is evidenced by the assembly of a talented team of scientists, augmented by our Board members, scientific advisors and a network of worldwide scientific and medical thought leaders.

Learn more…